18889881171
Kalkine 0
countryflagUS

Bruker Corporation

Healthcare US BRKR

39.21USD
-0.66(1.66%)

Last update at 2025-06-13T16:47:00Z

Day Range

39.0439.91
LowHigh

52 Week Range

53.7294.86
LowHigh

Fundamentals

  • Previous Close 39.87
  • Market Cap11025.11M
  • Volume736744
  • P/E Ratio28.31
  • Dividend Yield0.26%
  • EBITDA561.90M
  • Revenue TTM3000.90M
  • Revenue Per Share TTM20.55
  • Gross Profit TTM 1307.00M
  • Diluted EPS TTM2.68

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 413.90M 393.60M 225.80M 280.40M 244.70M
Minority interest -1.90000M -3.50000M 7.60M 0.80M 1.30M
Net income 296.60M 277.10M 157.80M 197.20M 179.70M
Selling general administrative 610.80M 564.50M 477.80M 500.20M 444.70M
Selling and marketing expenses -3.40000M -3.30000M -9.20000M - -
Gross profit 1305.70M 1209.60M 939.80M 995.30M 900.00M
Reconciled depreciation 88.00M 89.10M 80.40M 75.60M 64.90M
Ebit 432.70M 413.30M 248.30M 300.90M 281.90M
Ebitda 550.40M 516.70M 353.60M 383.00M 346.80M
Depreciation and amortization 117.70M 103.40M 105.30M 82.10M 64.90M
Non operating income net other -18.80000M -19.70000M -22.50000M -20.50000M -17.70000M
Operating income 432.70M 413.30M 248.30M 300.90M 262.40M
Other operating expenses 2068.30M 1990.30M 1714.30M 1765.20M 1613.70M
Interest expense 16.10M 14.30M 14.40M 16.00M 12.60M
Tax provision 116.40M 113.00M 64.40M 82.40M 63.70M
Interest income 4.10M 0.90M 3.20M 1.30M 1.20M
Net interest income -18.80000M -19.70000M -22.50000M -14.70000M -11.40000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 116.40M 113.00M 64.40M 82.40M 63.70M
Total revenue 2530.70M 2417.90M 1987.50M 2072.60M 1895.60M
Total operating expenses 843.30M 782.00M 666.60M 687.90M 618.10M
Cost of revenue 1225.00M 1208.30M 1047.70M 1077.30M 995.60M
Total other income expense net -18.80000M -19.70000M -22.50000M -20.50000M -19.50000M
Discontinued operations - - - - -
Net income from continuing ops 298.50M 280.60M 168.90M 198.00M 181.00M
Net income applicable to common shares 296.60M 277.10M 157.80M 197.20M 179.70M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4249.90M 3618.50M 3650.00M 3047.90M 2771.50M
Intangible assets 330.50M 270.90M 211.80M 229.10M 603.50M
Earning assets - - - - -
Other current assets 85.80M 202.60M 176.60M 165.50M 172.00M
Total liab 2836.60M 2486.70M 2565.20M 2072.30M 1854.40M
Total stockholder equity 1377.20M 1125.70M 1084.60M 975.60M 917.10M
Deferred long term liab - 62.30M 46.00M 43.10M 48.80M
Other current liab 454.90M 487.10M 481.20M 467.60M 388.80M
Common stock 1.70M 1.70M 1.70M 1.70M 1.70M
Capital stock 1.70M 1.70M 1.70M 1.70M 1.70M
Retained earnings 2323.80M 1926.00M 1659.50M 1406.50M 1274.70M
Other liab - 318.20M 404.90M 389.40M 311.00M
Good will 582.60M 457.60M 339.50M 320.40M 293.00M
Other assets - 208.90M 160.90M 180.00M 77.30M
Cash 488.30M 645.50M 1068.20M 681.80M 678.30M
Cash and equivalents - - - - -
Total current liabilities 1202.10M 913.80M 938.50M 793.60M 645.60M
Current deferred revenue 400.00M 225.70M 197.50M 189.20M 137.90M
Net debt 891.30M 573.70M 266.00M 209.70M 182.00M
Short term debt 144.50M 18.70M 112.40M 2.20M 0.50M
Short long term debt 121.20M 18.70M 112.40M 2.20M 0.50M
Short long term debt total 1379.60M 1219.20M 1334.20M 891.50M 860.30M
Other stockholder equity -954.30000M -816.80000M -568.40000M -436.30000M -333.80000M
Property plant equipment - 487.00M 406.10M 395.50M 306.10M
Total current assets 2164.20M 2124.50M 2471.80M 1924.90M 1796.30M
Long term investments - - - - -
Net tangible assets - 1210.90M 312.50M 509.60M 491.50M
Short term investments 12.00M 100.00M 100.00M 50.00M 6.60M
Net receivables 621.80M 472.70M 416.90M 335.30M 362.20M
Long term debt 1160.30M 1200.50M 1221.80M 842.30M 812.80M
Inventory 968.30M 803.70M 710.10M 692.30M 577.20M
Accounts payable 202.70M 182.30M 147.40M 134.60M 118.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 11.90M 14.10M 13.10M 10.30M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 6.00M 14.80M -8.20000M 3.70M -25.50000M
Additional paid in capital - - - - -
Common stock total equity - 1.70M 1.70M 1.70M 1.70M
Preferred stock total equity - - - - -
Retained earnings total equity - 1926.00M 1659.50M 1406.50M 1274.70M
Treasury stock - -1085.00000M -820.30000M -667.00000M -543.80000M
Accumulated amortization - - - - -
Non currrent assets other 175.70M -76.80000M 70.80M 39.60M 16.80M
Deferred long term asset charges - - - - -
Non current assets total 2085.70M 1494.00M 1178.20M 1123.00M 975.20M
Capital lease obligations 98.10M 51.20M 59.70M 47.00M 67.60M
Long term debt total - 1200.50M 1221.80M 842.30M 812.80M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -438.50000M -239.30000M -50.30000M -36.50000M -6.40000M
Change to liabilities - 30.80M 100.60M 57.40M 29.00M
Total cashflows from investing activities - -251.60000M -192.40000M -192.70000M -158.40000M
Net borrowings - 0.30M 489.60M -8.40000M 462.60M
Total cash from financing activities -193.40000M -415.20000M 318.70M -161.60000M 300.00M
Change to operating activities - 2.60M -19.20000M 11.00M -49.80000M
Net income 427.20M 298.50M 280.60M 161.40M 198.00M
Change in cash -157.20000M -423.00000M 386.20M 3.60M 355.60M
Begin period cash flow 645.50M 1071.70M 685.50M 681.90M 326.30M
End period cash flow 488.30M 648.70M 1071.70M 685.50M 681.90M
Total cash from operating activities 350.10M 262.00M 282.40M 333.20M 213.40M
Issuance of capital stock 6.80M 2.80M 7.00M 3.30M 10.90M
Depreciation 114.90M 88.00M 89.10M 80.40M 75.60M
Other cashflows from investing activities - -168.40000M 10.00M -59.00000M -79.00000M
Dividends paid 29.40M 29.80M 24.20M 24.60M 25.00M
Change to inventory -125.00000M -140.10000M -67.00000M -87.90000M -60.20000M
Change to account receivables -0.90000M -67.90000M -95.30000M 40.80M -5.00000M
Sale purchase of stock -152.30000M -263.10000M -153.30000M -123.20000M -142.30000M
Other cashflows from financing activities 0.30M -14.10000M 492.40M 288.70M 837.90M
Change to netincome - 12.90M 41.40M -6.50000M 4.20M
Capital expenditures 106.90M 119.00M 92.00M 98.20M 73.00M
Change receivables - -67.90000M -95.30000M 40.80M -5.00000M
Cash flows other operating - 49.20M 26.20M 90.30M -28.20000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -392.50000M 408.70M -22.10000M 355.00M
Change in working capital -87.80000M -143.50000M -125.20000M 76.00M -74.50000M
Stock based compensation 24.00M 27.70M 17.20M 16.00M 9.60M
Other non cash items -103.80000M 8.10M 26.50M 24.80M 10.10M
Free cash flow 243.20M 143.00M 190.40M 235.00M 140.40M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BRKR
Bruker Corporation		 -0.66 1.66% 39.21 28.31 31.95 4.07 8.75 4.37 19.16
ABT
Abbott Laboratories		 0.30 0.22% 136.75 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 1.38 0.36% 381.87 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.3142 0.36% 88.18 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.94 1.97% 100.50 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Bruker Corporation

40 Manning Road, Billerica, MA, United States, 01821

Key Executives

Name Title Year Born
Dr. Frank H. Laukien Ph.D. Chairman, CEO & Pres 1960
Mr. Gerald N. Herman Exec. VP & CFO 1958
Dr. Mark R. Munch Ph.D. Corp. Exec. VP and Pres of Bruker Nano Group & Corp. 1962
Mr. Juergen Srega Pres of Bruker CALID Group & Bruker Daltonics Division 1955
Dr. Falko Busse Ph.D. Pres of Bruker BioSpin Group 1967
Mr. Justin Joseph Ward Sr. Director of Investor Relations & Corp. Devel. NA
Mr. J. Brent Alldredge J.D. Gen. Counsel 1975
Mr. Collin J. D'Silva Pres of Chemical Analysis Division 1957
Stacey Desrochers Treasurer & Director of Investor Relations NA
Mr. Urban Faeh Pres of Bruker Optics Division & Managing Director of Bruker Optik GmbH NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.